Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
INGELHEIM & HAMBURG & MARCY-L’ÉTOILE -- Businesswire -- Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
The resulting company, Aurobac Therapeutics SAS, will combine the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of growing resistance to antibiotics in patients.
“The rise of antibiotic-resistant infections - also called antimicrobial resistance, or AMR - is indeed a looming global crisis,” said Michel Pairet, Head of Boehringer Ingelheim’s Innovation Unit and Member of the Board of Managing Directors. “Antibiotic resistance kills about 1.27 million people globally every year[1] and it has been estimated that by 2050, as many as 10 million worldwide deaths could result from AMR[2], making it potentially deadlier than cancer.”
Werner Lanthaler, CEO of Evotec added: “The grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial therapies. We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMérieux, to combine our complementary strengths. By leveraging Evotec’s multimodality approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR.”
“bioMérieux has a strong expertise in antimicrobial resistance. We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship),” said Alexandre Mérieux, bioMérieux Chairman and CEO. “Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results. This participation in Aurobac is perfectly aligned with bioMérieux’ full commitment to sustain antibiotic efficacy for future generations.”
Aurobac will work to shift the strategy related to antibiotic treatment regimens which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.
Funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each, the 40 million EUR joint venture, which has its headquarters in Lyon (France), combines the world leading expertise of Evotec, one of the most active research companies in infectious diseases, with bioMérieux’s market-leading expertise in infectious disease diagnostics and with Boehringer Ingelheim’s broad drug discovery and significant clinical development capabilities.
Three partners committed to combat AMR
Boehringer Ingelheim’s participation in Aurobac is part of a wider so-called pandemic preparedness initiative, which includes a 50 million EUR investment in the AMR action fund by Boehringer Ingelheim. Boehringer Ingelheim Venture Fund has committed to invest up to 12 million EUR in AMR infection companies.
bioMérieux has over 55 years of diagnostics expertise with more than 75 percent of its research and development budget focused on antimicrobial resistance. Moreover, 80 percent of its turnover is related to the fight against AMR through a complete diagnostic solution facilitating antibiotic therapy decision-making, including antibiotic initiation, optimization, and discontinuation.
Evotec has built a world-leading platform to tackle infectious diseases. With a more than 200-strong anti-infective discovery team, the company has proven experience on multiple agent classes. On top of the company’s own pre-competitive pandemic preparedness and rapid response technology platform (“PRROTECT”), Evotec leverages its infectious disease capabilities with many industry, academic and non-profit partners and is active in a variety of networks such as the AMR Accelerator that is part of the EU’s Innovative Medicines Initiative (“IMI”).
References [1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext#seccestitle10 [2] https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
Please click on the following link for ‘Notes to Editors’ and ‘References’:
https://www.boehringer-ingelheim.com/media-overview/press-releases/joint-venture-fight-antimicrobial-resistance
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005880/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Boehringer Ingelheim
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자, 2024년 3분기 잠정실적 발표 - 뉴스와이어
- 효성하이드로젠, 전남 광양에 첫 액화수소충전소 준공 - 뉴스와이어
- 대학내일20대연구소, 드라마·예능 속 Z세대 가치관 분석 보고서 발표 - 뉴스와이어
- SK행복나눔재단, 엑셀러레이팅 프로그램 ‘프로테제’로 청년 혁신가들 돕는다 - 뉴스와이어
- 미사경정공원, 핑크뮬리와 함께 가을의 낭만 속으로 - 뉴스와이어
- 한국의집, 뱅앤올룹슨 협업으로 색다른 문화 경험 선보여 - 뉴스와이어
- KB금융그룹, 영국 ‘브랜드 파이낸스사’ 선정 국내 최고 금융 브랜드 등극 - 뉴스와이어
- ‘2024 구로구 오류버들시장 오류버들축제’ 개최 - 뉴스와이어
- 투썸플레이스, 조니워커 블랙라벨 프리미엄 위스키 케이크 한정 출시 - 뉴스와이어
- 한국콤파스, AI 기반 통합 마케팅 솔루션과 함께 새로운 온라인 바이어 발굴 서비스 출시 - 뉴스